San Diego, 92126, CA,
United States
Seqster Technographics
Discover the latest software purchases and digital transformation initiatives being undertaken by Seqster and its business and technology executives. Each quarter our research team identifies on-prem and cloud applications that are being used by the 250 Seqster employees from the public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources.
During our research, we have identified that Seqster has purchased the following applications: Tripleblind SecuriKey for AML, Fraud and Compliance in 2022 and the related IT decision-makers and key stakeholders.
Our database provides customer insight and contextual information on which enterprise applications and software systems Seqster is running and its propensity to invest more and deepen its relationship with Tripleblind or identify new suppliers as part of their overall Digital and IT transformation projects to stay competitive, fend off threats from disruptive forces, or comply with internal mandates to improve overall enterprise efficiency.
We have been analyzing Seqster revenues, which have grown to $55.0 million in 2024, plus its IT budget and roadmap, cloud software purchases, aggregating massive amounts of data points that form the basis of our forecast assumptions for Seqster intention to invest in emerging technologies such as AI, Machine Learning, IoT, Blockchain, Autonomous Database or in cloud-based ERP, HCM, CRM, EPM, Procurement or Treasury applications.
TRM
Vendor |
Previous System |
Application |
Category |
Market |
VAR/SI |
When |
Live |
Insight |
|---|---|---|---|---|---|---|---|---|
| Tripleblind | Legacy | Tripleblind SecuriKey | AML, Fraud and Compliance | TRM | n/a | 2022 | 2022 |
In 2022, Seqster announced a partnership with TripleBlind to enable de-identified, tokenized, real-time health data sharing and analysis across EHRs, genomics, wearables and other sources in the United States. The announcement documents use of TripleBlind's privacy-preserving data collaboration capabilities to advance healthcare data interoperability between clinical and research stakeholders.
The public disclosure references privacy and tokenization workflows and implies potential adoption of Tripleblind SecuriKey to support controls aligned to AML, Fraud and Compliance, while the source does not explicitly state a SecuriKey deployment. Tripleblind SecuriKey is described here as the named application tied to the partnership, and if implemented it would typically provide key management, tokenization, and privacy-preserving access controls that map to AML, Fraud and Compliance functional terminology.
Operational scope described in the announcement centers on cross-source integrations across electronic health records, genomic repositories, and consumer wearable streams to enable governed, de-identified analytics. Governance signals emphasize consented data sharing, token lifecycle management, and controlled analytic access, indicating process changes around privacy-first interoperability rather than detailing specific AML program workflows.
|
| First Name | Last Name | Title | Function | Department | Phone | |
|---|---|---|---|---|---|---|
| No data found | ||||||
| Date | Company | Status | Vendor | Product | Category | Market |
|---|---|---|---|---|---|---|
| No data found | ||||||